Consolidated Statements of Equity - USD ($) shares in Millions, $ in Millions	Total	Shareholders’ Equity [Member]	Common Stock [Member]	Add’l Paid-In Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]		Non-controlling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury (in shares)					(3,840)
Beginning balance, common (in shares) at Dec. 31, 2020			9,407
Beginning balance at Dec. 31, 2020	$ 63,473	$ 63,238	$ 470	$ 88,674	$ (110,988)	$ 90,392	$ (5,310)		$ 235
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	22,025	21,979				21,979			45
Other comprehensive income/(loss), net of tax	(589)	(587)					(587)	[1]	(3)
Cash dividends declared:
Common stock	(8,816)	(8,816)				(8,816)
Noncontrolling interests	(8)								(8)
Share-based payment transactions (in shares)			64		(11)
Share-based payment transactions	1,470	1,470	$ 3	1,917	$ (373)	(77)
Other	(92)	(85)		0	$ 0	(85)			(7)
Ending balance, common (in shares) at Dec. 31, 2021			9,471
Ending balance, treasury (in shares) at Dec. 31, 2021					(3,851)
Ending balance at Dec. 31, 2021	77,462	77,201	$ 473	90,591	$ (111,361)	103,394	(5,897)		262
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury (in shares)					(3,851)
Net income	31,407	31,372				31,372			35
Other comprehensive income/(loss), net of tax	(2,422)	(2,407)					(2,407)	[1]	(15)
Cash dividends declared:
Common stock	(9,037)	(9,037)				(9,037)
Noncontrolling interests	(13)								(13)
Share-based payment transactions (in shares)			48		(13)
Share-based payment transactions	513	513	$ 2	1,192	$ (608)	(73)
Purchases of common stock (in shares)					(39)
Purchases of common stock	(2,000)	(2,000)			$ (2,000)
Other	$ 6	19		19		0			(13)
Ending balance, common (in shares) at Dec. 31, 2022	9,519		9,519
Ending balance, treasury (in shares) at Dec. 31, 2022	(3,903)				(3,903)
Ending balance at Dec. 31, 2022	$ 95,916	95,661	$ 476	91,802	$ (113,969)	125,656	(8,304)		256
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury (in shares)	(3,903)				(3,903)
Net income	$ 2,158	2,119				2,119			39
Other comprehensive income/(loss), net of tax	331	343					343	[1]	(12)
Cash dividends declared:
Common stock	(9,316)	(9,316)				(9,316)
Noncontrolling interests	(8)								(8)
Share-based payment transactions (in shares)			43		(12)
Share-based payment transactions	208	208	$ 2	829	$ (518)	(106)
Other	$ 0	0		0		0			0
Ending balance, common (in shares) at Dec. 31, 2023	9,562		9,562
Ending balance, treasury (in shares) at Dec. 31, 2023	(3,916)				(3,916)
Ending balance at Dec. 31, 2023	$ 89,288	$ 89,014	$ 478	$ 92,631	$ (114,487)	$ 118,353	$ (7,961)		$ 274
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury (in shares)	(3,916)				(3,916)

[1] Foreign currency translation adjustments include net losses in 2023, 2022 and 2021 related to the impact of our net investment hedging program and our equity-method investment in Haleon/the Consumer Healthcare JV (see Note 2C).